Extensively drug-resistant tuberculosis, Burkina Faso

Emerging Infectious Diseases

Volumn 16, Issue 5, 2010, Pages 840-842

  Saleri, Nuccia ^a,b   Badoum, Gisèle ^c   Ouedraogo, Martial ^c   Dembélé, Sary M ^a   Nacanabo, Rachel ^a   Bonkoungou, Victor ^d   Cirillo, Daniela ^e   Pinsi, Gabriele ^f   Matteelli, Alberto ^a,b  

^a MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^d National Global Fund Coordination   (Burkina Faso)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f Institute of Microbiology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BURKINA FASO; CASE REPORT; DRUG MONITORING; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SPUTUM ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTITUBERCULAR AGENTS; BURKINA FASO; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FATAL OUTCOME; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 77951158376     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1605.091262     Document Type: Article

References (10)

1. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrugresistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47:496-502. DOI: 10.1086/590005
2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. DOI: 10.1016/S0140-6736(06)69573-1
3. World Health Organization. Countries with XDR-TB confirmed cases as of June 2008 [cited 2009 Aug 18]. http://www.who.int/tb/challenges/xdr/xdr_map_june08.pdf
4. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2009. WHO/HTM/TB/2008.411. Geneva: The Organization; 2008.
5. World Health Organization. WHO anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. Geneva: The Organization; 2008.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva: The Organization; 2008.
7. Andrews JR, Gandhi NR, Moodley P, Shah S, Bohlken L, Moll AP, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis. 2008;198:1582-9. DOI: 10.1086/592991
8. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weenzembeek CS, et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health. 2002;7:970-6. DOI: 10.1046/j.1365-3156.2002.00960.x
9. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5:887-93.
10. Chen-Yuan C, Enarson DA, Fujiwara PI, Van Deun A, Jen-Jyh L. Strategies of extensively drug- resistant TB risk management for health workers and other care givers. Expert Review of Respiratory Medicine. 2008;2:47-54 [cited 2010 Feb 25]. http://www.expert-reviews.com/toc/ers/2/1